Diabetes

Thomas C. Blevins, MD, ECNU, FACE, FNLA, provides an overview of biosimilars and discusses interchangeability status among biosimilars such as for insulin glargine-yfgn for the management of diabetes.

An investigation looks into how the incidence of type 1 diabetes changed during the first year of the COVID-19 pandemic.

A study published in the Journal of the American Academy of Dermatology did a prospective analysis on psoriasis biologic treatment response related to comorbid obesity and a history of diabetes.

Type 1 diabetes requires patients to have knowledge and skill to manage medication and potential complications.

Automation in closed-loop systems improves type 1 diabetes outcomes and glucose profiles in teens, according to a study published in JAMA Pediatrics.

The prevalence of insulin pump use for Black beneficiaries increased from 3.9% to 4.6% between 2017 and 2019.

The addition of a pharmacist to a diabetes management team increases therapy optimization and medication access while enhancing patient care.

Prescription fills decreased most significantly in a subgroup of adults.

Lockdown orders impacted how diabetes care was provided for new onset T1D.

Drs Thomas C. Blevins and Diana Isaacs share insight on unmet needs and the future treatment landscape of biosimilars in the treatment of patients with diabetes.

Thomas C. Blevins, MD, ECNU, FACE, FNLA, leads the discussion on potential challenges to the adoption of biosimilars in clinical practice, such as for insulin glargine-yfgn in diabetes management, and discusses the importance of patient and provider education.

Thomas C. Blevins, MD, ECNU, FACE, FNLA, and Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, discuss the impact of interchangeable insulin biosimilars on biologic products in the marketplace for diabetes management.

The FDA has approved finerenone (Kerendia, Bayer) for the treatment of adults with chronic kidney disease (CKD) associated with type 2 diabetes.

Learn more about controlling pediatric type 1 diabetes through pharmacist recommendations and families who address common misconceptions.

The CDC estimates that 83 million Americans have prediabetes and that 84% of them don’t know it and community pharmacy can play a major role in preventing diabetes.

Although the authors say their findings shed light on possible disruptions to insulin supply during COVID-19, they note they could not adjust for those with diabetes who died.

Five medications are currently approved by the FDA for chronic weight management.

The FDA has granted approval of the first interchangeable biosimilar insulin product, insulin glargine-yfgn (Semglee; Mylan Pharmaceuticals), for diabetes.

The FDA has approved the AstraZeneca once-weekly injectable therapy for use in children aged 10 to 17 years.

At the virtual Scientific Sessions for the American Diabetes Association, Jennifer Sherr, MD, discussed the findings of a study of the Omnipod 5 automated insulin delivery system in very young children with type 1 diabetes.

An oral abstract presentation at the American Diabetes Association Virtual 81st Scientific Sessions highlighted a cardioprotective benefit of sodium-glucose co-transporter-2 inhibitors.

At the virtual Scientific Sessions for the American Diabetes Association, a study shows that metformin can improve adolescent type 1 diabetes.

A study presented at the American Diabetes Association Virtual 81st Scientific Sessions compared flash glucose monitoring with self-monitoring of blood glucose in patients with diabetes and moderate-to-advanced chronic kidney disease.

A study presented at the American Diabetes Association Virtual 81st Scientific Sessions evaluated metformin prescribing for patients with type 2 diabetes and chronic kidney disease.

A poster presented at the American Diabetes Association Virtual 81st Scientific Sessions highlighted the effect of a physician-pharmacist collaborative management team in diabetes preventative care services.